Daclatasvir · Daklinza, BMS-790052

What is Daclatasvir?

Daclatasvir is an orally available inhibitor of the hepatitis C virus non-structural protein 5A (NS5A), which it binds in domain I to disrupt the viral RNA replication complex. It is used in combination with sofosbuvir for chronic hepatitis C virus infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Daklinza, BMS-790052, EBP 883

Drug type

Small molecule

Targets

HCV non-structural protein 5A (NS5A)

Mechanism

Inhibitor of HCV non-structural protein 5A (NS5A)

Pathways

HCV RNA replication complex disruption, viral RNA replication

Therapy area

Infectious disease

Developer

Bristol-Myers Squibb

In trials of

AVIR

FDA status

Approved as Daklinza (July 24, 2015), NDA206843 · FDA label

UNII

LI2427F9CI

✅ FDA-approved uses

• Chronic hepatitis C virus (HCV) genotype 1 or 3 infection, with sofosbuvir, with or without ribavirin

From the indications section of the FDA label (version of Oct 16, 2019). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Hepatitis CHCV InfectionHepatitis CHepatitis C Virus InfectionHepatitis C, Chronic

Sources

• FDA label (DailyMed)
• FDA label Daklinza (2019-10-16), indications
• NCI Thesaurus
• ClinicalTrials.gov NCT04019717

Updated Oct 11, 2026.